Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anetumab ravtansine - Bayer HealthCare

Drug Profile

Anetumab ravtansine - Bayer HealthCare

Alternative Names: Anti-mesothelin antibody-drug conjugate BAY 94-9343; Anti-mesothelin-ADC-BAY-94-9343; BAY-94-9343; BAY-94-9343-SPDB-DM4

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; ImmunoGen; MorphoSys; National Cancer Institute (USA)
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Belgium (IV, Infusion)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Moldova (IV, Infusion)
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Spain (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top